Intra-cellular Drug Patent Portfolio
Intra-cellular owns 1 orange book drug protected by 25 US patents Given below is the list of Intra-cellular's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11753419 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | 10 Dec, 2040 | Active |
| US12122792 | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | 10 Dec, 2040 | Active |
| US12090155 | Methods | 07 Jul, 2040 | Active |
| US11980617 | Methods of treating acute depression and/or acute anxiety | 27 Oct, 2039 | Active |
| US10695345 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US11052084 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US11690842 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US11806348 | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US12070459 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US12128043 | Pharmaceutical capsules comprising lumateperone mono-tosylate | 30 Aug, 2039 | Active |
| US10960009 | Methods of treating schizophrenia and depression | 03 Dec, 2034 | Active |
| US11026951 | Methods of treating bipolar disorder | 03 Dec, 2034 | Active |
| US9956227 | Method for the treatment of residual symptoms of schizophrenia | 03 Dec, 2034 | Active |
| USRE48839 | Methods and compositions for sleep disorders and other disorders | 19 Aug, 2033 | Active |
| US8598119 | Methods and compositions for sleep disorders and other disorders | 28 Dec, 2029 | Active |
| US8648077 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | 01 Dec, 2029 | Active |
| US10117867 | Methods and compositions for sleep disorders and other disorders | 27 May, 2029 | Active |
| US9168258 | Methods and compositions for sleep disorders and other disorders | 27 May, 2029 | Active |
| US9616061 | Methods and compositions for sleep disorders and other disorders | 27 May, 2029 | Active |
| US9199995 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | 12 Mar, 2029 | Active |
| US9586960 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | 12 Mar, 2029 | Active |
| USRE48825 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | 12 Mar, 2029 | Active |
| US10464938 | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof | 12 Mar, 2028 | Active |
| US7183282 | Substituted heterocycle fused γ-carbolines | 15 Jun, 2020 | Expired |
| USRE39680 | Substituted heterocycle fused gamma-carbolines | 15 Jun, 2020 | Expired |
Latest Legal Activities on Intra-cellular's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Intra-cellular.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 30 Jan, 2024 | US11806348 |
| Mail Patent eCofC Notification | 30 Jan, 2024 | US11806348 |
|
Email Notification
Critical
| 30 Jan, 2024 | US11806348 |
| Recordation of Patent eCertificate of Correction | 30 Jan, 2024 | US11806348 |
| Post Issue Communication - Certificate of Correction | 10 Jan, 2024 | US11806348 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Nov, 2023 | US10695345 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Nov, 2023 | US11806348 |
|
Email Notification
Critical
| 07 Nov, 2023 | US11806348 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11806348 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11806348 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Nov, 2023 | US11806348 |
| Patent eGrant Notification | 07 Nov, 2023 | US11806348 |
|
Email Notification
Critical
| 31 Oct, 2023 | US11690842 |
| Mail Pub Notice re 312 amendment | 31 Oct, 2023 | US11690842 |
| Post Issue Communication - Certificate of Correction | 27 Oct, 2023 | US11690842 |
Intra-cellular Drug Patents' Oppositions Filed in EPO
Intra-cellular drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 27, 2022, by Sandoz Ag. This opposition was filed on patent number EP14867061A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14867061A | Apr, 2022 | Sandoz AG | Granted and Under Opposition |
Intra-cellular's Family Patents
Intra-cellular drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 32.5% of its total global patent coverage. Click
below to unlock the full patent family tree.
Intra-cellular Drug List
Given below is the complete list of Intra-cellular's drugs and the patents protecting them.
1. Caplyta
Caplyta is protected by 26 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11753419 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
10 Dec, 2040
(15 years from now)
| Active |
| US12122792 | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
10 Dec, 2040
(15 years from now)
| Active |
| US12090155 | Methods |
07 Jul, 2040
(15 years from now)
| Active |
| US11980617 | Methods of treating acute depression and/or acute anxiety |
27 Oct, 2039
(14 years from now)
| Active |
| US10695345 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US11052084 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US11690842 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US11806348 | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US12070459 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US12128043 | Pharmaceutical capsules comprising lumateperone mono-tosylate |
30 Aug, 2039
(14 years from now)
| Active |
| US10960009 | Methods of treating schizophrenia and depression |
03 Dec, 2034
(9 years from now)
| Active |
| US11026951 | Methods of treating bipolar disorder |
03 Dec, 2034
(9 years from now)
| Active |
| US9956227 | Method for the treatment of residual symptoms of schizophrenia |
03 Dec, 2034
(9 years from now)
| Active |
| USRE48839 | Methods and compositions for sleep disorders and other disorders |
19 Aug, 2033
(8 years from now)
| Active |
| US8598119 | Methods and compositions for sleep disorders and other disorders |
28 Dec, 2029
(4 years from now)
| Active |
| US8648077 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
01 Dec, 2029
(4 years from now)
| Active |
| US10117867 | Methods and compositions for sleep disorders and other disorders |
27 May, 2029
(4 years from now)
| Active |
| US9168258 | Methods and compositions for sleep disorders and other disorders |
27 May, 2029
(4 years from now)
| Active |
| US9616061 | Methods and compositions for sleep disorders and other disorders |
27 May, 2029
(4 years from now)
| Active |
| US9199995 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
12 Mar, 2029
(4 years from now)
| Active |
| US9586960 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
12 Mar, 2029
(4 years from now)
| Active |
| USRE48825 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
12 Mar, 2029
(4 years from now)
| Active |
| USRE48825 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
12 Feb, 2029
(4 years from now)
| Active |
| US10464938 | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
12 Mar, 2028
(3 years from now)
| Active |
| US7183282 | Substituted heterocycle fused γ-carbolines |
15 Jun, 2020
(4 years ago)
| Expired |
| USRE39680 | Substituted heterocycle fused gamma-carbolines |
15 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caplyta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List